A new industry report reveals Latham & Watkins advised on a record $370bn in tech, media, and telecom deals last year, narrowly edging out rivals in a highly competitive legal advisory market.
With hyperscalers projected to pour $500 billion into AI infrastructure by 2026, investors are looking beyond headline chipmakers to the essential, yet often overlooked, backbone providers of the AI revolution.
Microsoft's second-quarter earnings smashed expectations, fueled by a 26% surge in cloud revenue that crossed the $50 billion mark for the first time. The tech giant's aggressive AI investments are now driving significant growth across its enterprise stack.
Cisco Systems has inked a major 15-year virtual power purchase agreement for solar energy in Poland, a move that extends its environmental commitments into one of Europe's more fossil-fuel-dependent grids and underscores its long-term capital allocation strategy beyond core tech.
Microsoft posts record cloud and AI-driven revenue for Q2, fueled by new partnerships and its custom AI chip. However, a significant surge in capital expenditures for AI infrastructure and a slight deceleration in Azure growth triggered the stock's worst single-day drop since 2020, testing investor resolve on the long-term payoff.
A fresh round of analyst price target adjustments for European asset manager Amundi (ENXTPA:AMUN) is prompting investors to recalibrate their expectations, placing renewed scrutiny on the firm's growth trajectory in a challenging macroeconomic climate.
German industrial giant Thyssenkrupp is exploring the sale of a significant minority stake in its Rothe Erde bearings division, a move analysts say could signal a broader portfolio reshuffle and highlight persistent valuation gaps within the conglomerate.
DuPont de Nemours launches a new ion exchange resin designed to boost productivity for organic acid producers in food, pharma, and bioplastics, as its stock shows sustained momentum.
The Bitcoin-to-gold ratio has slumped close to its 2017 level, fueling a fresh round of scrutiny over the cryptocurrency's viability as a long-term store of value amidst a resurgent precious metals market and persistent macroeconomic uncertainty.
Visa's fiscal first-quarter earnings surpassed expectations, driven by robust cross-border transactions and a surge in high-margin digital services. The payments giant signals confidence in sustained consumer resilience despite some moderation in U.S. debit volumes.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
In its Q4 2025 earnings call, SL Green Realty projected strong fundamentals for Manhattan's office market, citing robust leasing and AI-driven demand. Management reiterated ambitious 2026 financing and asset sale targets while reporting quarterly results that beat expectations.
Despite a persistently muted demand environment, Sherwin-Williams reported robust fourth-quarter earnings, driven by cost discipline and strategic acquisitions. The paint giant forecasts low-to-mid single-digit sales growth for 2026 while reinstating employee benefits, signaling cautious optimism amid ongoing economic headwinds.
Freedom Capital Markets has lowered its price target for Li Auto (NASDAQ: LI) from $34 to $25, citing a mixed quarterly performance and a challenging outlook as China's electric vehicle sector grapples with a fierce price war and softening demand.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
H.C. Wainwright has trimmed its price target on Genmab following mixed Phase 3 results for its lymphoma drug EPKINLY, though maintains a Buy rating, citing precedent and ongoing trials.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Analysts at Stifel have initiated coverage on sports data giant Sportradar Group AG (NASDAQ: SRAD) with a Buy rating and a $28 price target, citing its dominant market position and favorable industry dynamics as online sports betting consolidates.
Analyst firm Stifel has initiated coverage on sports data giant Genius Sports with a Hold rating, praising its foundational role in the online betting ecosystem but flagging a balanced risk-reward at current levels.
RBC Capital has reaffirmed its confidence in Ascendis Pharma, raising its price target following the company's ambitious 2026 strategic goals, which hinge on sustained momentum for its lead therapy and significant long-term revenue targets.
